Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03593954 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants

A Phase 1 study of Healthy, sponsored by Janssen Research & Development.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT03593954 is a Phase 1 study of Healthy that has completed, run by Janssen Research & Development. The registered enrollment target is 12 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03593954, a Phase 1 study of Healthy, has completed, sponsored by Janssen Research & Development.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The primary purpose of this study is to assess the effect of ritonavir, on the single-dose pharmacokinetics (PK) of JNJ-61393215 in healthy participants.

Conditions Studied

Interventions

  • DRUG Ritonavir
  • DRUG JNJ-61393215

Study Locations (1)

Utah

  • PRA International - Salt Lake City

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2018-07-31
Est. Completion 2018-09-19
Phase Phase 1

Sponsor

Janssen Research & Development

593 total trials

What the Registry Record Tells You About NCT03593954

The ClinicalTrials.gov registry entry for NCT03593954 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Ritonavir is the first listed.

NCT03593954 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT03593954 about?

NCT03593954 is a clinical study titled "A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants". The primary purpose of this study is to assess the effect of ritonavir, on the single-dose pharmacokinetics (PK) of JNJ-61393215 in healthy participants.

What is the current status of trial NCT03593954?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-07-31. Estimated completion is 2018-09-19.

What conditions does trial NCT03593954 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT03593954?

The interventions under investigation include: Ritonavir (DRUG), JNJ-61393215 (DRUG).

Who is sponsoring clinical trial NCT03593954?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03593954 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.